| Literature DB >> 32276831 |
Sarah E Kovar1, Cody Fourman2, Christine Kinstedt2, Brandon Williams2, Christopher Morris2, Kwang-Jin Cho3, Daniel M Ketcha4.
Abstract
Ras proteins are small GTPases which regulate cellular proliferation, differentiation, and apoptosis. Constitutively active mutant Ras are expressed in ~15-20% human cancers, and K-Ras mutations account for ~85% of all Ras mutations. Despite the significance of Ras proteins in refractory cancers, there is no anti-Ras drug available in clinic. Since K-Ras must interact with the plasma membrane (PM) for biological activity, inhibition of the K-Ras/PM interaction is a tractable approach to block oncogenic K-Ras activity. Here, we discovered chalcones 1 and 8 exhibit anti-K-Ras activity, and show that the compounds mislocalize K-Ras from the PM and block oncogenic K-Ras signal output. Also, 1 inhibits the growth of K-Ras-driven human cancer cells. Our data suggest that 1 could be a promising starting point for developing anti-K-Ras cancer drug.Entities:
Keywords: K-Ras; K-Ras-driven cancer; Mislocalization; Plasma membrane; Trimethoxy chalcone
Mesh:
Substances:
Year: 2020 PMID: 32276831 PMCID: PMC7216516 DOI: 10.1016/j.bmcl.2020.127144
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823